Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
aberrant, back, bear, bid, biometric, broader, CCPA, Circuit, cited, citing, collateral, collateralized, commerce, complaint, conclusion, consecutive, contemplated, CorporateCentre, customary, default, departure, domestic, driven, droplet, economy, Eversana, FTC, FTCA, GDPR, genetic, geopolitical, global, HHS, illegal, impractical, intranasal, Kingdom, leaving, medium, member, Mexican, mutually, notification, onboarding, opt, outbreak, premium, prepaid, prepay, regain, regained, remanded, resubmission, revolving, root, split, strain, stronger, transposed, unconstitutional, unsecured, unstable, upheld
Filing tables
Filing exhibits
Related press release
EVOK similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Evoke Pharma, Inc.
Solana Beach, California
We hereby consent to the incorporation by reference in Registration Statements on Form S-3 (No. 333-221556) and Form S-8 (Nos. 333-224897, 333-219960, 333-211302 and 333-191518) of Evoke Pharma, Inc. (the “Company”) of our report dated March 12, 2020, relating to the financial statements, which appears in this Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
/s/ BDO USA, LLP
San Diego, California
March 12, 2020